Early detection and monitoring of Multiple Sclerosis

The MS detection and the decision about its pharmacological treatment is based on the observation of the symptoms and the monitoring of magnetic resonance imaging (MRI) showing the evolution of characteristic lesions of the disease. FractalMed can support an early detection not related to the existence of outbreaks or visible signs of lesion.
Automated system to obtain the fractal dimension

FractalMed automates the process to obtain the fractal dimension values in order to directly characterize the structure of interest from the brain magnetic resonance.
Conclusive preclinical outcomes

Currently it has preclinical conclusive outcomes. Our project ha successfully exceeded the concept test and we are now in the international multicentric pre-regulatory validation phase.

FractalMed application areas

These are some of the FractalMed application areas

Detection of brain disorder in brain resonance imaging in normal appearing.

Clinically isolated syndrome patients type show changes on the FD of the white and grey matter in normal appearing before the lesions appear.

Monitoring the development of MS

The FD varies significantly depending on the type of MS, so it allows for parameterization of the monitoring and therefore the tracking of the disease.

Detection of brain disorder in prematures.

We have obtained results regarding detection of brain disorder in premature infants who suffered intrauterine growth restriction and premature birth even when the brain imaging was appearing normal.

Detection of brain disorder in other neurological diseases with resonance imaging appearing normal.

Some changes have been detected in the FD of the brain imaging of patients with other neurological diseases such us Schizophrenia, Alzheimer and Parkinson amongst others.

Detection of changes in normal brain aging.

A change in the FD of the brain structures while using resonance imaging of normal individuals during their aging has also been revealed.

Monitoring of the evolution of brain tumors.

It is been shown that the FD allows the monitoring of neuroradiological brain tumors with antiangiogenic treatments.

Learn more about FractalMed benefits and applications

+ Information

Latest news and publications

These are some of the latest news published by FractalMed

Presentation at the Barcelona Healthcare Investment Forum 2015

On October 7, 2015, FractalMed will assist at the 15th Barcelona Healthcare Investment Forum 2015 (15è Fòrum d’Inversió H...